Patent · US Active

Respiratory syncytial virus vaccine

US9409973B2 · kind B2 · utility

3Cited by

1References

12Claims

0Family size

Assignees

VIB VZW · BE
UNIVERSITEIT GENT · BE

Inventors

Xavier Saelens · Ieper, BE
Bert Schepens · Evergem, BE
Walter Fiers · Laarne, BE

Key dates

Filing date	Nov 15, 2011
Grant date	Aug 9, 2016
Priority date	—
Expiry date	May 19, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/18571
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or a pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.